Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus HN001 and Reduced Eczema Prevalence

Research synthesisLow evidenceLarge effect3 studies · 1 beneficial · 2 neutral · 0 harmful

Across 3 studies, 1 reported a large beneficial effect of Lactobacillus rhamnosus HN001 on reducing eczema prevalence, while 2 found neutral (small) effects. The most-studied dose was 6 × 10^9 CFU daily, and the populations were primarily pregnant and breastfeeding mothers and their infants, including high-risk birth cohorts. Evidence base is small (only 3 studies) — conclusions should be considered preliminary, and many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests.

  • Effective dose range: 6 × 10^9 colony-forming units daily
  • Studied populations: Pregnant and breastfeeding mothers and their children (including high-risk birth cohorts)

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. The sole beneficial study may reflect differences in population (high-risk cohort) or treatment protocol (infant combined with maternal supplementation). Study durations were not consistently reported, limiting assessment of onset of effect.

Generated Jul 12, 2026
Doses used in studies
  • CFU/day: 6 billion (median 6 billion, IQR 6 billion–6 billion) — 3 studies
Safety in these studies
3 of 3 papers
Back to top